Retrospective Study of the Effects of Sub-pathologic Phenotypes of BP on Clinical Management and Prognosis

Launched by XIJING HOSPITAL · Jan 10, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a skin condition called Bullous Pemphigoid (BP), which mainly affects older adults and can lead to serious health issues. The researchers want to understand how different types of BP impact treatment and long-term outcomes for patients. By looking back at the medical records of patients diagnosed with BP at Xijing Hospital, they will collect information about patients’ age, gender, health history, symptoms, and treatment responses. This information can help doctors better manage BP and improve care for patients in the future.

To be eligible for this study, participants must be diagnosed with Bullous Pemphigoid at Xijing Hospital and be between 0 and 100 years old, regardless of gender. They should have complete skin biopsy information and must not have received certain medications like steroids or immunosuppressants in the month prior to their diagnosis. If enrolled, participants can expect to contribute to valuable research that may benefit future patients with this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (1) Patients with Bullous Pemphigoid who were first hospitalized in the Department of Dermatology of Xijing Hospital
• • (2) Age 0-100 years old, gender is not limited.
• • (3) Diagnosis is confirmed by clinical, histopathologic, immunopathologic and/or anti-BP180 antibody tests.
• • (4) Complete skin histopathology information
• Exclusion Criteria:
• • (1) Patients with Bullous Pemphigoid who were not first diagnosed in our hospital.
• • (2) Those who have received systemic glucocorticoid, immunosuppressant, biologic, or other drug therapy within the past month.